AstraZeneca puts further $75M up for grabs in expanded Proteros cancer drug deal
AstraZeneca puts further $75M up for grabs in expanded Proteros cancer drug deal
gmasson
Thu, 05/12/2022 - 14:52
As Siemens AG leaves Russia over Ukraine war, Siemens Healthineers will stay
As Siemens AG leaves Russia over Ukraine war, Siemens Healthineers will stay
chale
Thu, 05/12/2022 - 14:31
Human Cell Atlas initiative makes strides as scientists piece together 'Google Map' of human cells
Human Cell Atlas initiative makes strides as scientists piece together 'Google Map' of human cells
aliu
Thu, 05/12/2022 - 13:43
Chutes & Ladders—Moderna CFO Gomez departs after just one day following unearthed investigation
Chutes & Ladders—Moderna CFO Gomez departs after just one day following unearthed investigation
mbayer
Thu, 05/12/2022 - 13:24
Paige nets European OK for AI to spot prostate cancer biomarkers
Paige nets European OK for AI to spot prostate cancer biomarkers
apark
Thu, 05/12/2022 - 11:57
GE Healthcare aims to bring prenatal ultrasound to the home, with investment in smartphone-scanner developer
GE Healthcare aims to bring prenatal ultrasound to the home, with investment in smartphone-scanner developer
chale
Thu, 05/12/2022 - 11:32
Mammogram-reading AI developer Therapixel snags €15M to expand US presence
Mammogram-reading AI developer Therapixel snags €15M to expand US presence
apark
Thu, 05/12/2022 - 09:59
Abbott, Women as One set up diversity-focused training program
Abbott, Women as One set up diversity-focused training program
aarmstrong
Thu, 05/12/2022 - 09:21
Bristol Myers provides Bridge over troubled water with $905M deal to enter SHP2 race
Bristol Myers provides Bridge over troubled water with $905M deal to enter SHP2 race
ntaylor
Thu, 05/12/2022 - 08:58
After 20 years, Boehringer vet hits the exit to become CEO at autoimmune biotech SciRhom
After 20 years, Boehringer vet hits the exit to become CEO at autoimmune biotech SciRhom
ntaylor
Thu, 05/12/2022 - 07:47
Bristol Myers on track for 3rd new drug launch of 2022 with latest deucravacitinib data
Bristol Myers on track for 3rd new drug launch of 2022 with latest deucravacitinib data
gmasson
Wed, 05/11/2022 - 21:55
Taiho claws back some licensing rights to lung cancer med from Cullinan in atypical, frontloaded deal
Taiho claws back some licensing rights to lung cancer med from Cullinan in atypical, frontloaded deal
mbayer
Wed, 05/11/2022 - 18:21
Caribou ready to uncork the chardonnay thanks to first-in-human CAR-T results
Caribou ready to uncork the chardonnay thanks to first-in-human CAR-T results
aarmstrong
Wed, 05/11/2022 - 15:19
Former Immunomedics CFO Usama Malik indicted for insider trading, pledging to dispute 'false and speculative narrative' at trial
Former Immunomedics CFO Usama Malik indicted for insider trading, pledging to dispute 'false and speculative narrative' at trial
gmasson
Wed, 05/11/2022 - 13:51
FTC orders Medtronic to sell off Intersect ENT subsidiary in antitrust review
FTC orders Medtronic to sell off Intersect ENT subsidiary in antitrust review
apark
Wed, 05/11/2022 - 11:52
BD, Babson set sights on bringing simple blood collection into the home
BD, Babson set sights on bringing simple blood collection into the home
chale
Wed, 05/11/2022 - 10:53
Welcome to New (Bio) Haven: CEO hopes to strike gold twice with remaining R&D crew after Pfizer deal
Welcome to New (Bio) Haven: CEO hopes to strike gold twice with remaining R&D crew after Pfizer deal
mbayer
Wed, 05/11/2022 - 10:45
Novo Nordisk, Flagship's forward-thinking partnership aims to treat cardiometabolic, rare diseases
Novo Nordisk, Flagship's forward-thinking partnership aims to treat cardiometabolic, rare diseases
gmasson
Wed, 05/11/2022 - 10:37
Bioasis, Neuramedy to cross blood-brain barrier together in $72M licensing deal
Bioasis, Neuramedy to cross blood-brain barrier together in $72M licensing deal
aarmstrong
Wed, 05/11/2022 - 10:23
Bioventus nixes $415M funding plan for CartiHeal acquisition, citing 'current market conditions'
Bioventus nixes $415M funding plan for CartiHeal acquisition, citing 'current market conditions'
apark
Wed, 05/11/2022 - 10:07